Benkowitz Michael's Form 4 filing
United Therapeutics Corp (UTHR) · filed Feb 3, 2026
- Accession no.
- 0001673232-26-000008
- Filed
- Feb 3, 2026
- Trade date
- Feb 2, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $10.6M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Benkowitz MichaelCIK 0001673232 | Officer (PRESIDENT AND COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | MOption exerciseAcquired | +14,625 | $117.76 | +$1,722,240 | 14,625 | Indirect | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −14,625 | $470.95 | −$6,887,643.75 | 0 | Indirect | |
| Feb 2, 2026 | Common Stock | MOption exerciseAcquired | +7,875 | $146.03 | +$1,149,986.25 | 7,875 | Indirect | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −7,875 | $470.95 | −$3,708,731.25 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | MOption exerciseDisposed | −14,625 | $0.00 | $0 | 38,625 | Indirect | |
| Feb 2, 2026 | Common Stock | MOption exerciseDisposed | −7,875 | $0.00 | $0 | 20,815 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.